Swiss startup Aeon lands €8.2M to fight preventable deaths through AI, early detection, and precision care

Zurich-based Aeon, a preventive health company, announced that it has secured €8.2M in a seed funding round led by London-based VC Concentric.

“Aeon is not just another testing solution. In our view, many consumer health products on the market today deliver questionable value,” says Alex Stroud, Principal at Concentric. “Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market. That rare combination of clinical rigor and commercial scalability is what makes this team so exciting.”

Others, including Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss super angel investor Daniel Gutenberg (known for backing 12 unicorns), participated in the round.

Fund utilisation

The Swiss company will use the funds to support its expansion across Switzerland, Germany, and the UK, with further international markets planned.

The capital will be used to build partnerships with insurers and employers, making healthcare more accessible and affordable, and to improve Aeon’s AI platform for faster and more accurate diagnostics.

Aeon plans to open more than 10 new locations in the coming months as it scales its clinical network.

Aeon: Building a new category of preventive health

According to the Global Alliance for Chronic Diseases, 41 million people die each year from non-communicable diseases (chronic illnesses that aren’t transmissible), a number projected to rise by 27 per cent by 2030.

Despite 80 per cent of these deaths being preventable, fragmented data and sluggish healthcare systems continue to stand in the way of effective prevention.

Founded in 2023 by Tim Seithe (CEO) and Samuel Frey (CPO), Aeon is a preventive health company offering AI-powered check-ups that combine whole-body MRI, blood biomarker analysis, and genetic testing.

With this, Aeon can detect and predict more than 500 diseases and health risks early.

These findings are reviewed by board-certified doctors and discussed with a radiologist, claims the company.

So far, the Swiss company has a 0 per cent false positive rate in clinical follow-ups, making it a standout in an area known for overdiagnosis and unnecessary treatments.

Aeon uses AI in three ways:

• Automated imaging analysis
• Cross-validation
• Predictive modeling

Since launching in 2024, the company has already helped detect early-stage cancers, aneurysms, Alzheimer’s, and other critical conditions, often in people who felt perfectly healthy.

The company claims to have identified undiagnosed kidney cancer in a 56-year-old man, leading to life-saving surgery.

It is also the first health platform to offer full-body check-ups eligible for reimbursement by health insurers, and has already signed deals with Switzerland’s largest insurance providers, including KPT.

Depending on the plan, customers can receive up to 80 percent of the cost back, setting a new precedent for accessible, proactive healthcare.

“We’re redefining preventive care by shifting it from reactive checks to proactive, personalised health management. Our approach goes beyond early disease detection — we’re tackling one of preventive medicine’s biggest challenges: false positives”, says Tim Seithe, Aeon’s founder and CEO. “Every customer receives a tailored risk profile, along with a clear, medically grounded plan to monitor and reduce their health risks over time.”